Injectable Influenza Vaccine 2027

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2DP26R0003

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued a solicitation (SPE2DP26R0003) for the procurement of injectable influenza vaccines for the 2027 season. This active solicitation seeks to secure a reliable supply of influenza vaccines to support the health and readiness of personnel across the United States, with the place of performance specified as within the USA. The scope of this procurement encompasses the manufacturing and delivery of injectable influenza vaccines, classified under NAICS code 325414, which pertains to Biological Product (except Diagnostic) Manufacturing. The selected contractor will be expected to provide vaccines that meet all applicable regulatory standards and quality requirements, ensuring timely and effective distribution to designated recipients as determined by DLA Troop Support. Key objectives of this solicitation include the provision of safe, effective, and FDA-approved injectable influenza vaccines, with an emphasis on consistent quality, adherence to delivery schedules, and compliance with all federal procurement and health regulations. The intended outcome is to maintain a robust immunization program for military and associated personnel, thereby supporting force health protection initiatives. Interested contractors should note that the solicitation is managed by DLA Troop Support, a federal office within the Defense Logistics Agency. The primary point of contact for this opportunity is Rosbert Jones ([email protected], 445-737-1254), with Melissa Rios Thomas ([email protected], 445-737-8646) listed as the secondary contact. All inquiries and submissions should be directed to these individuals as specified in the solicitation documents. The procurement is being conducted as a formal solicitation, and all interested parties are encouraged to review the full solicitation details and any associated attachments available through the official SAM.gov opportunity listing (Opportunity ID: 3e68eba2449d40a5b375db7ff6d1e935). The notice was posted on April 11, 2026, and responses are due by March 12, 2026, at 20:12. Contractors considering this opportunity should ensure their capabilities align with the requirements for large-scale biological product manufacturing, specifically injectable influenza vaccines, and be prepared to demonstrate compliance with all applicable federal standards. No specific set-aside requirements or special considerations are indicated in the provided information; however, all standard federal procurement protocols will apply. This solicitation represents a significant opportunity for qualified manufacturers to support a critical public health initiative within the Department of Defense, with long-term implications for force readiness and health protection.